DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

ZTS·Zoetis Inc.

$.
+. (+.%)
After Hours
High
$77.00
Open
$75.86
Market Cap
32.91B
52W High
$161.77
Low
$75.25
P. Close
$75.52
P/E
12.45
52W Low
$71.47
Fwd P/E
10.22
DailyIQ Est.
$119.71
Technical Score (1D)
36
SELL
News Sentiment
79
BULLISH
ZTS received European Commission approval for its single‑dose Poulvac Procerta HVT‑ND vaccine that protects chickens against Newcastle and Marek’s diseases, expanding its EU poultry portfolio. The approval allows the product to be administered in ovo or subcutaneously at hatch, simplifying vaccination schedules for producers and potentially accelerating adoption. This regulatory win could lift sales in the EU poultry market over the next few weeks as distributors begin to roll out the vaccine, giving ZTS a competitive edge over rivals. Traders should monitor the pace of EU sales rollout and any pricing decisions, as early uptake will determine whether the approval translates into revenue growth. In parallel, HSBC, Barclays, and TD Cowen have all trimmed their price targets for ZTS, citing concerns over earnings outlook and competitive pressures, which may weigh on short‑term sentiment. The lowered targets reflect a more conservative valuation stance, so watch the upcoming Q3 earnings release for guidance on revenue and margin expectations to gauge whether the market will adjust. A securities class action alleging material misstatements about product adoption has been filed, raising the risk of regulatory scrutiny and potential volatility. The lawsuit’s progress, including any settlement or court ruling, will be a key watch item, as it could impact investor confidence and the stock’s risk profile. Overall, the EU approval offers a near‑term upside catalyst, while the valuation cuts and litigation risk create a balanced view that traders should keep an eye on earnings, sales data, and legal developments over the next trading days.
Earnings Summary
Zoetis Inc. is a global animal‑health company that develops and markets medicines, vaccines, diagnostics, and services for livestock and companion animals, operating in the specialty drug manufacturing sector. The firm’s broad portfolio spans parasiticides, vaccines, and diagnostics for cattle, swine, poultry, dogs, and cats, positioning it as a key player in a growing market that demands innovative, single‑dose solutions. In the most recent two quarters, Zoetis reported EPS of $1.48 in Q4 2025 and $1.53 in Q1 2026, both below the analyst estimates of $1.616 and $1.615, respectively, marking a decline from the $1.76 and $1.70 EPS achieved in Q2 and Q3 2025; revenue also fell from $2.46 B in Q2 2025 to $2.387 B in Q4 2025 and then to $2.262 B in Q1 2026, after a peak of $2.46 B in Q2 2025. Historically, the company has posted EPS beats in four of the last six quarters—Q4 2024, Q1 2025, Q2 2025, and Q3 2025—while missing in Q4 2025 and Q1 2026, indicating a pattern of strong early‑quarter performance that has recently softened. The European Commission’s approval of the Poulvac Procerta HVT‑ND vaccine is a material development that could lift short‑term revenue as distributors roll out the single‑dose product; investors should watch early sales data in the next quarter to gauge market uptake and supply‑chain capacity. Concurrently, a securities class action alleging fraud around sales of Librela and Simparica Trio introduces regulatory scrutiny that could affect future earnings guidance, while HSBC’s downgrade to $95 reflects growing analyst concern over growth prospects. Going forward, investors should watch for early sales figures of the new poultry vaccine, updates on the litigation status, and any guidance revisions that address margin pressure and input costs, as these factors will shape the company’s near‑term earnings trajectory.

EPS

EstBeatMiss
$1.33$1.48$1.63$1.78$1.93Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.86 - -
Q1'26$1.62$1.53-5.3%
Q4'25$1.62$1.48-8.4%
Q3'25$1.62$1.70+4.8%
Q2'25$1.61$1.76+9.2%
Q1'25$1.40$1.48+5.8%

Revenue

EstBeatMiss
$2.2B$2.3B$2.4B$2.5B$2.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.5B - -
Q1'26$2.3B$2.3B-2.8%
Q4'25$2.3B$2.4B+3.1%
Q3'25 - $2.4B -
Q2'25 - $2.5B -
Q1'25 - $2.2B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ZTS Stock Snapshot

ZTS is currently trading at $76.00, giving Zoetis Inc. a market cap of 32.91B and a P/E ratio of 12.4. Today's range spans $75.25–$77.00, with shares opening at $75.86 and moving up $0.48 (0.6%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 79/100.

Over the past year ZTS has traded between $71.47 and $161.77 - the current price is +6.3% off the 52-week low and -53.0% from the high. 26 analysts cover the stock with a Hold consensus and a mean 12-month target of $115.65 (range $85.00–$160.00), implying upside of +52.2%.

ZTS sits at $76.00 (near 52-week lows) with a HOLD technical read (36/100) and bullish sentiment (79/100). The 32.91B market cap in Healthcare (P/E: 12.4) makes this a name that institutional coverage maintains even through neutral phases - which means any catalyst shift will be quickly priced in. Annual range: $71.47–$161.77.

The 52-week range of $71.47–$161.77 for ZTS provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $76.00 (near 52-week lows), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 36/100 and bullish news backdrop (79/100) don't break the tie yet, but they narrow the probability distribution toward the upside.